Concert: Concert Pharma is acquuired by Sun Pharma and with it deuruxolitinib a proposed treatment for Alopecia Areata.

Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") and Concert Pharmaceuticals, Inc. announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value.